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ABSTRACT
QT prolongation is a serious adverse drug effect, which is associated with an increased risk of Torsade de pointes and sud-
den death. Many drugs, including both cardiac and non-cardiac drugs, have been reported to cause prolongation of QT in-
terval. Although meperidine has not been considered proarrhythmic, we present a unique case of a 16-year-old boy without 
an underlying cardiac disease, who developed polymorphic ventricular tachycardia, ventricular fibrillation and QT prolon-
gation after an intravenous meperidine injection. He had no mutation in long QT syndrome genes (KCNQ1, KCNH2, and 
SCN5A), but single nucleotide polymorphisms were reported, including H558R in SCNA5A and K897T in KCNH2. (Korean 
Circ J 2011;41:342-345)
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 Introduction
Long QT syndrome (LQTS) is a disorder of myocardial 
repolarization characterized by a prolonged QT interval on 
an electrocardiogram (ECG), leading to Torsade de pointes 
(TdP) and ventricular fibrillation. QT prolongation may be 
congenital or acquired. In the acquired form of the syn-
drome, some medications have been confirmed to cause QT 
prolongation and TdP, which is the main reason for the 
withdrawal or restriction of the use of drugs that have al-
ready been marketed.
1) Methadone, one of the opioid com-
pounds, is well known to have a dose-response relationship 
with corrected QT (QTc) interval.
2) Meperidine hydrochlo-
ride (Demerol
®) is another synthetic opioid analgesic fre-
quently prescribed for pain control. However, no adverse 
drug effects on arrhythmia have been reported. Here, we re-
port a case of a patient with meperidine-induced QT pro-
longation and life-threatening polymorphic ventricular 
tachycardia.
 
Case
A 16-year-old boy complained of chest tightness and diz-
ziness immediately after an intravenous meperidine injec-
tion for pain control before a colonoscopy. 
He had a history of generalized tonic-clonic seizure at the 
age of thirteen and had been taking valproate. His brain 
MRI was normal and his EEG showed generalized spike 
waves, implying generalized epilepsy. Otherwise, he was 
healthy and had no family history of syncope or sudden 
death. As he had complained of cramping abdominal pain 
with diarrhea 2-3 times per week for one year before this 
event, he was scheduled for a colonoscopy under the suspi-
cion of inflammatory bowel disease. Initially, his vital signs 
were stable and his heart rate was 72 beats/min. After a me-
peridine injection for pain control before the colonoscopy, 
he complained of chest discomfort and lost consciousness. 
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ventricular fibrillation and cardiopulmonary resuscitation 
was performed (Fig. 1). The patient was successfully defi-
brillated with 300 Joules of direct current energy. After 
pulseless ventricular arrhythmia, his ECG showed a pro-
longed QTc interval, over 500 msec, and serum electrolytes 
were within the normal range. His QTc interval remained 
prolonged at 597 msec and his rhythm remained sinus bra-
dycardia at 54 bpm the day after the event (Fig. 2). His QTc 
intervals normalized slowly over the following 3 days. He 
was transferred to our hospital 5 days after the event, show-
ing a normal QTc interval of 424 msec and a heart rate of 67 
bpm. To establish the repolarization abnormality, an epi-
nephrine challenge test was performed.
3) The QTc interval 
became prolonged up to 567 msec from the baseline (398 
msec) 30 seconds after the epinephrine bolus injection (0.1 
µg/kg), followed by continuous infusion (0.1 µg/kg/min) 
(Fig. 3A and B). The steady state QTc was 425 msec. Both 
the treadmill exercise test and 24-hour holter monitoring 
were normal, and there were no cardiac abnormalities seen 
on the echocardiogram. We performed a genetic analysis for 
3 genes encoding essential channel subunits, including 
KCNQ1 (LQT1), KCNH2 (LTQ2), and SCN5A (LQT3). 
Fig. 1. Ventricular fibrillation at the time of cardiac arrest.
Fig. 2. Electrocardiogram the day after ventricular fibrillation developed. QTc interval is 591 msec.
Fig. 3. Epinephrine test results. Six days after cardiopulmonary resuscitation, baseline electrocardiogram reveals normal QTc interval (A: 
QTc 431 msec), but 30 seconds after epinephrine bolus injection (0.1 µg/kg), followed by continuous infusion (0.1 µg/kg/min), QTc interval 
became prolonged up to 587 msec (B). Two years after cardiopulmonary resuscitation, epinephrine test shows normal (C: QTc 418 msec).
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There was no related mutation, but 12 single nucleotide 
polymorphisms (SNPs), including H558R in SCNA5A and 
K897T in KCNH2, were reported in these genes. He also 
carried E1601E, D1819D, A29A, IVS9 and IVS10 variants in 
SCN5A, L564L; Y652Y and IVS13 variants in KCNH2; and 
A370A and P448R variants in KCNQ1. The patient had had 
a follow-up ECG, which had demonstrated normal QT in-
tervals. There was no significant abnormality in the ST seg-
ment on the ECG during the follow-up period. After 1.5 
years, he underwent an electrophysiological study. There 
was no QT prolongation after isoproterenol injection and 
arrhythmia was not induced by a pacing study. A treadmill 
exercise test, 24-hour holter monitoring, and an epinephrine 
test were repeated, showing neither abnormalities in rhythm 
nor QT prolongation (Fig. 3C). He experienced no chest 
tightness, dizziness, or syncope thereafter. He took a beta-
blocker for 22 months after ventricular fibrillation and sub-
sequently stopped taking medication. He was advised not to 
take meperidine or other QT-prolonging drugs.
Discussion
The acquired form of LQTS is a potentially fatal medical 
condition, which can be exacerbated by a wide range of both 
cardiac and non-cardiac medications. Many of the drugs 
initially known to prolong QT intervals were Ia and III anti-
arrhythmics.
4)5) However, many non-cardiac drugs have also 
been reported to cause QT prolongation, accounting for 
2-3% of the total drug prescriptions in the UK and Italy.
6) 
Drugs which are generally considered to confer a risk of 
TdP, are antibiotics (macrolides and quinolones), antidepres-
sants (tricyclics and selective serotonin reuptake inhibitors), 
antipsychotics (haloperidol and phenothiazines), and anti-
emetics (ondansetron and prochlorperazine). Most of these 
agents exhibit direct electrophysiological effects on cardiac 
ion channels, usually by blocking rapidly activating delayed 
rectifier (repolarizing) potassium current (IKr). Many drugs, 
however, block multiple cardiac ion channels (IKr, IKs, and 
INa) leading to a more complex shift of action potential mor-
phology.
1) These conditions cause a cardiac repolarization 
delay, inducing TdP. The HERG (human ether-à-go-go-re-
lated gene, alternative nomenclature KCNH2) is responsible 
for channels mediating IKr which plays an important role in 
ventricular repolarization. Pharmacological inhibition of 
native IKr and recombinant HERG channels is a shared fea-
ture of diverse drugs associated with TdP.
7) 
Meperidine or pethidine (commonly referred to as Dem-
erol
®) is an opioid analgesic drug. Katchman et al.
8) de-
scribed the ability that opioid compounds have in influenc-
ing the cardiac HERG → KCNH2 K
+ current, IHERG. In 
opioids, L-α-acetylmethadol (LAAM) and methadone block 
IHERG in transfected cells at clinically relevant concentrations, 
which could explain the mechanisms for adverse cardiac ef-
fects observed in some patients receiving LAAM or metha-
done. Meperidine was less potent in IHERG inhibition than 
LAAM or methadone, but it is postulated that meperidine 
may act as a QT-prolonging drug by blocking IHERG in the 
study patient. 
Multiple clinical risk factors for drug-induced TdP have 
been identified; female gender, hypokalemia, bradycardia, 
congestive heart failure, high drug concentrations, rapid in-
travenous infusion with a QT-prolonging drug, severe hy-
pomagnesemia, subclinical LQTS, ion channel polymor-
phism, and base-line QT prolongation. Bradycardia is more 
likely to cause exaggerated QT prolongation in susceptible 
patients than in non-susceptible patients.
9) In our patient, 
injection of intravenous meperidine induced bradycardia, 
which may have aggravated QT prolongation. The latter 
could explain the lengthening of cardiac repolarization ob-
served in this patient receiving clinical doses of meperidine. 
Valproate, which he had been taking at the time, is not 
known to have an interaction with meperidine.
It has been recognized that drug-induced QT prolonga-
tion may depend on a genetic substrate.
9-13) Several research-
ers have suggested that 5% to 10% of patients with drug-in-
duced TdP have DNA variants in the coding regions of con-
genital long-QT disease genes and may have a subclinical 
form of the congenital disease.
9)10)14) It has also been shown 
that not only rare mutations but also polymorphisms in LQ-
TS genes could represent risk factors for drug-induced ar-
rhythmia. In addition, some allelic variants were reported to 
influence QTc length even in healthy individuals, and may 
represent risk factors for arrhythmias or cardiac sudden 
death.
15-17)
Our patient had no mutation associated with LQT1, LQT2, 
or LQT3, which account for most cases of LQTS. Neverthe-
less, he had 12 SNPs in the coding region and flanking re-
gion of SCN5A, KCNH2, and KCNQ1. P448R and A370A 
SNPs in KCNQ1 (LQT1), K897T, L564L; Y652Y SNPs in KC-
NH2 (LQT2), H558R, E1601E, D1819D, A29A; and IVS9 
1141-3C>A SNPs in SCN5A (LQT3), were previously report-
ed in drug-induced LQTS patients.
11) Among them, H558R 
in SCN5A, a relatively common polymorphism present in 
20-30% population, is associated with a prolonged QTc in-
terval.
14)16) K897T in KCNH2 is another common polymor-
phism and was reported to be associated with either short QT 
interval or long QT interval.
18)19) H558R in SCN5A and K897T 
in KCNH2 have been confirmed to alter channel physiology 
and cardiac ion channel function, which may create a vul-
nerable substrate in the presence of appropriate triggers such 
as IKr blockers, precipitating life-threatening ventricular ar-
rhythmias.
16)20) Therefore, we speculated that meperidine mig-
ht be the trigger of ventricular arrhythmia and QT prolongat-
ion in this patient, with underlying functional polymorphisms Mi Kyoung Song, et al.   345
in the congenital LQTS genes. 
In conclusion, there have been numerous non-arrhythmic 
drugs that can cause QT prolongation and TdP. However, 
meperidine has not previously been reported as a QT pro-
longing agent. This patient’s genetic analysis revealed SNPs 
in congenital LQTS, including H558R in SCN5A and 
K897T in KCNH2. We reported a case of meperidine-in-
duced QT prolongation in a patient with SNPs in congenital 
LQTS genes. Meperidine is commonly used for children 
and adults before painful procedures. Therefore we should 
be fully aware of this fact and continue to carefully monitor 
proarrhythmic effects attributable to meperidine. 
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